hackint0sh/New-Dataset huggingface dataset:
nctId: NCT06336876 id: 080.EDU.2019.R briefTitle: Perceived Coping, Meaning, and Joy at Work overallStatus: RECRUITING date: 2020-06-30 date: 2024-12 date: 2024-12 date: 2024-03-29 date: 2024-03-29 name: Methodist Health System class: OTHER briefSummary: The aim of this study is to assess and describe employee characteristics associated with perceived horizontal inter-collegial workplace uncivil behavior within nursing services, and identify any relationships with meaning and joy in work (MJW), and assess job satisfaction. conditions: Undefined studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: HEALTH_SERVICES_RESEARCH masking: NONE count: 84 type: ESTIMATED name: Survey measure: Workplace Incivil Behavior measure: Meaning, Joy in Work measure: Occupational Coping Self-Efficacy measure: Demographic sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Methodist Richardson Medical Center status: RECRUITING city: Richardson state: Texas zip: 75082 country: United States name: Maxine Adegbola, RN role: CONTACT phone: 214-876-9767 email: maxineadegbola@mhd.com name: Maxine Adegbola, RN role: PRINCIPAL_INVESTIGATOR name: David Irvan, RN role: SUB_INVESTIGATOR name: Terri Daugherty, RN role: SUB_INVESTIGATOR name: Joanna Bender, RN role: SUB_INVESTIGATOR name: Tabitha Moore, RN role: SUB_INVESTIGATOR name: Sharon Blackerby, RN role: SUB_INVESTIGATOR name: Katherine Hartdegen, RN role: SUB_INVESTIGATOR name: Melissa Miller, RN role: SUB_INVESTIGATOR name: Shannon Jackson, RN role: SUB_INVESTIGATOR name: Obed Thomas, RN role: SUB_INVESTIGATOR lat: 32.94818 lon: -96.72972 hasResults: False
nctId: NCT06336863 id: STU-2023-1151 briefTitle: Use of DNA Testing and Gene Expression Profiling to Help Transition Kidney Transplant Recipients to Belatacept-only Immunosuppression overallStatus: NOT_YET_RECRUITING date: 2024-04 date: 2026-08 date: 2026-12 date: 2024-03-29 date: 2024-04-05 name: University of Texas Southwestern Medical Center class: OTHER briefSummary: The purpose of the study is to provide immunosuppression weaning and/or monitoring for an additional 12-months to evaluate the safety and efficacy of belatacept monotherapy in patients previously enrolled in the clinical trial: "Use of donor derived-cell free DNA (AlloSure) and gene expression profiling (AlloMap Kidney) to facilitate Belatacept monotherapy in kidney transplant patients." conditions: Kidney Transplant Immunosuppression studyType: INTERVENTIONAL phases: NA allocation: NON_RANDOMIZED interventionModel: SEQUENTIAL primaryPurpose: TREATMENT masking: NONE count: 24 type: ESTIMATED name: Allosure and TruGraf name: Immunosuppression Taper measure: Incidence of acute kidney graft rejection measure: Incidence of facilitation to Belatacept monotherapy measure: Patient Survival after Immunosuppression Wean measure: Kidney Graft Failure after Immunosuppression Wean measure: Mean change in Estimated Glomerular Filtration Rate (eGFR) after Immunosuppression Wean measure: Incidence of Proteinuria after Immunosuppression Wean measure: Incidence of de-novo donor specific antibodies (dnDSA) sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: University of Texas Southwestern Medical Center city: Dallas state: Texas zip: 75390 country: United States name: David Wojciechowski, DO role: PRINCIPAL_INVESTIGATOR lat: 32.78306 lon: -96.80667 typeAbbrev: Prot_SAP hasProtocol: True hasSap: True hasIcf: False label: Study Protocol and Statistical Analysis Plan date: 2024-03-06 uploadDate: 2024-03-28T09:25 filename: Prot_SAP_000.pdf size: 293395 hasResults: False
nctId: NCT06336850 id: 069.GID.2020.D briefTitle: Safety and Efficacy of Endoscopic Ultrasound-Guided Portal Pressure Gradient Measurement overallStatus: RECRUITING date: 2020-12-23 date: 2025-01-01 date: 2025-01-01 date: 2024-03-29 date: 2024-03-29 name: Methodist Health System class: OTHER briefSummary: The purpose of this study is to evaluate the efficacy, safety, and adequacy of Endoscopic Ultrasound (EUS) Portal Pressure Gradient Measurement (PPGM) in patients undergoing EUS-guided liver biopsies. conditions: Liver Diseases studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: DIAGNOSTIC masking: NONE count: 100 type: ESTIMATED name: Endoscopic Ultrasound-Guided Portal Pressure Gradient Measurement measure: Portal Pressure Gradient Measurements from Hepatic and Portal Veins measure: Correlation between Portal Pressure Gradient Measurements and the presence or absence of portal hypertension measure: Clinical significance between portal pressure gradient measurement and portal hypertension sex: ALL minimumAge: 18 Years maximumAge: 85 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Methodist Dallas Medical Center status: RECRUITING city: Dallas state: Texas zip: 75203 country: United States name: Prashant Kedia, MD role: CONTACT lat: 32.78306 lon: -96.80667 hasResults: False
nctId: NCT06336837 id: 24-3T/48 briefTitle: False Positive Peripheral Blood Culture in Children With Leukaemia: A Prevalence Study overallStatus: RECRUITING date: 2024-03-15 date: 2024-06-01 date: 2024-12-01 date: 2024-03-29 date: 2024-04-01 name: Ege University class: OTHER briefSummary: Chemotherapy, the main treatment for childhood leukemia, has side effects on healthy cells. One of the most important of these side effects is the risk of infection due to neutropenia. In clinics, blood culture is the gold standard for the detection of possible infection risk (bacteremia, fungemia, etc.). During the diagnosis and treatment process in children with leukemia, a large number of peripheral or catheter blood cultures are performed. When the culture results are positive, it is accepted that the infection has grown. In some cases, a positive peripheral blood culture result may not be clinically significant. An agent belonging to the skin flora of the patient or the healthcare professional taking the field culture may also cause the blood culture result to be positive. This is called contamination or false positive blood culture. Contaminated cultures may cause prolonged hospitalization, additional medical interventions, unnecessary initiation of antibiotic treatment and related antibiotic resistance, toxicity due to additional drugs and an increase in hospital costs. The peripheral blood culture contamination rate, which is accepted as a quality indicator in some countries, should be below 3%.
In this context, this study aimed to determine the prevalence of false positive peripheral blood cultures by examining the peripheral blood culture results obtained during routine follow-ups from children hospitalized with leukemia in the pediatric hematology clinic. The data will be collected retrospectively covering three years before March 2024 when the ethics committee approval was obtained. Since the relevant clinic cares for approximately 25 new children diagnosed with leukemia annually, the study sample is planned as 75 cases. conditions: Nurse's Role conditions: Leukemia studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: RETROSPECTIVE count: 75 type: ESTIMATED measure: blood culture contamination rate sex: ALL minimumAge: 0 Years maximumAge: 18 Years stdAges: CHILD stdAges: ADULT facility: Ege University status: RECRUITING city: İzmir zip: 35100 country: Turkey name: Seda ARDAHAN SEVGILI, PhD role: CONTACT phone: 00905544318390 email: sedardahan@gmail.com name: Figen YARDIMCI, PhD role: CONTACT email: figenyardimci@gmail.com lat: 38.41273 lon: 27.13838 hasResults: False
nctId: NCT06336811 id: DEU active-pasive VR briefTitle: Virtual Reality Distraction During Phlebotomy in Children acronym: activeVR overallStatus: COMPLETED date: 2023-05-30 date: 2023-12-30 date: 2023-12-30 date: 2024-03-29 date: 2024-03-29 name: Dokuz Eylul University class: OTHER briefSummary: This randomized controlled study was conducted to evaluate the effect of distraction methods using virtual reality on the emotional appearance, pain, fear, and anxiety associated with the procedure during phlebotomy in children aged 6-12 in a private blood collection unit. conditions: Pain, Acute conditions: Child, Only conditions: Anxiety and Fear studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: SUPPORTIVE_CARE masking: SINGLE maskingDescription: Before blood collection, the "Emotional Appreance Scale for Children" was evaluated by a non-researcher nurse. Pediatric patients between the ages of 6 and 12, from whom blood would be collected, were distributed to groups according to the randomization scheme. whoMasked: INVESTIGATOR count: 150 type: ACTUAL name: passive virtual reality distraction name: active virtual reality distraction measure: procedure related pain measure: anxiety measure: fear measure: emotional apperance sex: ALL minimumAge: 6 Years maximumAge: 12 Years stdAges: CHILD facility: Gülçin Özalp Gerçeker city: İzmir zip: 35100 country: Turkey lat: 38.41273 lon: 27.13838 hasResults: False
nctId: NCT06336798 id: STUDY00005871 id: K23HL166775 type: NIH link: https://reporter.nih.gov/quickSearch/K23HL166775 briefTitle: Bioenergetic Effect of Pioglitazone in CLD-PH overallStatus: NOT_YET_RECRUITING date: 2024-05 date: 2028-08 date: 2028-08 date: 2024-03-29 date: 2024-04-01 name: Emory University class: OTHER name: National Heart, Lung, and Blood Institute (NHLBI) briefSummary: The goal of this clinical trial is to learn about the safety and efficacy of Pioglitazone in people with Pulmonary Hypertension (PH) due to Chronic Lung Disease (CLD). The main question it aims to answer is:
Participants will be asked to take pioglitazone or placebo once daily for 28 days followed by a washout period of 2 weeks followed by 28 days of the other study drug (participants randomized to placebo followed by pioglitazone or pioglitazone followed by placebo). conditions: Pulmonary Hypertension conditions: Pulmonary Hypertension Due to Lung Diseases studyType: INTERVENTIONAL phases: PHASE2 allocation: RANDOMIZED interventionModel: CROSSOVER primaryPurpose: TREATMENT masking: DOUBLE whoMasked: PARTICIPANT whoMasked: INVESTIGATOR count: 20 type: ESTIMATED name: Pioglitazone 30mg name: Placebo name: Labs measure: Change in Mitochondrial metabolism parameters: Spare respiratory capacity measure: Change in Mitochondrial metabolism parameters: Maximal respiration measure: Change in Mitochondrial metabolism parameters: Basal respiration measure: Number of hypoglycemia incidences measure: Number of participants with leg edema measure: Change in BNP levels measure: Change in Six minute walk distance (6MWT) measure: Change in Borg dyspnea score measure: Change in NYHA/WHO Functional Classification measure: Change in University of California San Diego Shortness of Breath Questionnaire score measure: Change in emPHasis-10 Questionnaire score sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06336785 id: 04-2023-HIT-K&S briefTitle: Kiss and Smile HIT overallStatus: RECRUITING date: 2023-11-02 date: 2024-11-30 date: 2025-11-30 date: 2024-03-29 date: 2024-04-01 name: Erevna Innovations Inc. class: OTHER briefSummary: The "Holistic Individualized Treatment" (HIT) approach is used to identify treatment priorities, focus areas, and appropriate products for soft tissue filler treatments.
The "Kiss and Smile HIT" considers lip volume, lip framing and expression to improve patients appearance. This trial will assess the effectiveness of the Kiss and Smile HIT algorithm in treating patients with different kiss and smile related issues (e.g. volume loss, lips lack proper framing, lack of a confident smile due to issues with expression). conditions: Aesthetic studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 24 type: ESTIMATED name: Restylane line of dermal fillers and Dysport neuromodulator measure: Global Aesthetic Improvement Scale (GAIS) sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Erevna Innovations Inc. status: RECRUITING city: Montréal state: Quebec zip: H3R3A1 country: Canada name: Andreas Nikolis, MD role: CONTACT phone: 514-488-0163 email: research@vicpark.com lat: 45.50884 lon: -73.58781 hasResults: False
nctId: NCT06336772 id: 10-2023-GAL-SHYP briefTitle: Restylane Shaype Versus Juvederm Volux for Chin Augmentation overallStatus: ACTIVE_NOT_RECRUITING date: 2023-10-23 date: 2024-10-31 date: 2024-11-01 date: 2024-03-29 date: 2024-04-01 name: Erevna Innovations Inc. class: OTHER briefSummary: This study aims to compare two injectable products (Restylane Shaype and Juvéderm Volux) for aesthetic augmentation of the chin conditions: Chin Retrusion studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: DOUBLE whoMasked: PARTICIPANT whoMasked: OUTCOMES_ASSESSOR count: 40 type: ACTUAL name: Restylane Shaype name: Juvéderm Volux measure: Statistically significant group differences in the average three-dimensional volumetric increase since baseline measure: Treatment group differences assessed by blinded evaluations on a validated chin retrusion scale (Galderma Chin Retrusion Scale) measure: Treatment group differences assessed by blinded evaluations of aesthetic improvement (Global Aesthetic Improvement Scale) measure: Assessment of product integration by means of ultrasound (the radius or surface area of in vivo product placed within tissues, integration [or lack thereof] of the product into the surrounding tissues) sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Erevna Innovations Inc. city: Montréal state: Quebec zip: H3R3A1 country: Canada lat: 45.50884 lon: -73.58781 hasResults: False
nctId: NCT06336759 id: 2021-10-GAL-JWL briefTitle: Safety and Efficacy of Fillers for Contouring the Jawline overallStatus: COMPLETED date: 2021-11-11 date: 2022-12-14 date: 2023-11-10 date: 2024-03-29 date: 2024-04-01 name: Erevna Innovations Inc. class: OTHER briefSummary: The study aims to evaluate the safety and efficacy of two hyaluronic acid products, Restylane Lyft and Defyne, for contouring the jawline and chin, addressing concerns about contour deficits in patients seeking aesthetic treatments. conditions: Jawline Contour Deficit studyType: INTERVENTIONAL phases: NA allocation: NON_RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: SINGLE whoMasked: OUTCOMES_ASSESSOR count: 40 type: ACTUAL name: Restylane Defyne name: Restylane Lyft measure: Frequency of subjects having at least "improved" since Baseline, as per the Global Aesthetic Improvement Scale (GAIS) measure: Frequency of subjects displaying at least a one grade improvement since Baseline, on the Raspaldo (2008) Jawline Scale measure: Frequency of subjects having at least "improved" since Baseline, as per the Global Aesthetic Improvement Scale (GAIS) measure: Frequency of subjects displaying at least a one grade improvement since Baseline, on the Raspaldo Jawline Scale sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Erevna Innovations Inc. city: Montréal state: Quebec zip: H3R3A1 country: Canada lat: 45.50884 lon: -73.58781 hasResults: False
nctId: NCT06336746 id: RHenningsson briefTitle: Effects of Steep Trendelenburg and Pneumoperitoneum on Cardiac Performance. overallStatus: NOT_YET_RECRUITING date: 2024-05-01 date: 2024-12-31 date: 2025-03-31 date: 2024-03-29 date: 2024-04-17 name: Karlstad Central Hospital class: OTHER briefSummary: The field of robotic-assisted laparoscopic surgery increases all the time. Older and more fragile patients which are not suitable for major open surgery could be scheduled for robotic- assisted surgery. The peroperative anesthesiological challenges and stresses during this type of surgery could anyway be even more prominent.
During surgery the work load and performance of the heart will be monitored using an esophageal doppler and optical spectrophotometry measuring regional saturation of the brain. This study can identify patients at risk of developing critical circulatory failure during this type of surgery. conditions: Heart Failure, Systolic conditions: Robotic Surgery studyType: OBSERVATIONAL observationalModel: CASE_CONTROL timePerspective: PROSPECTIVE count: 80 type: ESTIMATED name: Esophageal Doppler measure: Change of Stroke Volume during Trendelenburg position and pneumoperitoneum. measure: % Change of Systemic Vascular Resistance;PulsePressureVariation; Peak Velocity; Stroke Volume Variation and FlowTimeCorrected measure: % change in regional brain saturation rSO2 during Trendelenburg position and pneumooperitoneum. sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Dpt of Anesthesiology&Intensive Care; Central Hospital of Karlstad city: Karlstad state: Värmland zip: 65230 country: Sweden name: Ragnar N Henningsson, Associate Professor role: CONTACT phone: +461083317434 email: ragnar.henningsson@regionvarmland.se lat: 59.3793 lon: 13.50357 hasResults: False
nctId: NCT06336733 id: APHP220828 briefTitle: Randomized Controlled Trial in Patients on Long-term Colchicine With Colchicine-resistant Familial Mediterranean Fever (FMF) to Evaluate the Efficacy of On-demand Anakinra Treatment for Painful Attacks in Patients Who Refuse Continuous Daily Therapy acronym: KIN-ATTACK-FMF overallStatus: NOT_YET_RECRUITING date: 2024-03 date: 2026-03-03 date: 2026-09-15 date: 2024-03-29 date: 2024-03-29 name: Assistance Publique - Hôpitaux de Paris class: OTHER briefSummary: To evaluate the efficacy on clinical symptoms in case of FMF attack among FMF patients resistant to Colchicine of
* compared to analgesic associated with daily colchicine in patients refusing continuous anti-IL-1 treatment. conditions: FMF studyType: INTERVENTIONAL phases: PHASE3 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: NONE count: 50 type: ESTIMATED name: ANAKINRA measure: Mean number of FMF-attacks per month at 6 months of treatment. measure: Cumulative days of FMF attack treatment measure: AIDAI (Auto-inflammatory Diseases activity index) score measure: Number of painful days and severity of FMF attacks occurring between randomization and M6 measure: Quality of life score measured by EuroQOL questionnaire (EQ-5D5L) measure: Number of local cutaneous reactions at 6 months (erythema and oedema involving the injection sites) in the anakinra arm measure: Proportion of Adverse events sex: ALL minimumAge: 6 Years stdAges: CHILD stdAges: ADULT stdAges: OLDER_ADULT facility: Service de Médecine interne Hopital Tenon city: Paris zip: 75020 country: France name: Léa SAVEY role: CONTACT phone: 00 33 1 56 01 60 77 email: lea.savey@aphp.fr name: Sophie Georgin-Lavialle, MD,PHD role: CONTACT phone: 0 33 1 56 01 74 31 email: sophie.georgin-lavialle@aphp.fr lat: 48.85341 lon: 2.3488 hasResults: False
nctId: NCT06336720 id: HMI-SA-PoNS-STK001 briefTitle: PoNS® Therapy for Gait and Balance Deficits in Chronic Stroke Survivors: A Single-Arm Study overallStatus: RECRUITING date: 2024-05-01 date: 2025-04-30 date: 2025-08-30 date: 2024-03-29 date: 2024-04-29 name: Helius Medical Inc class: INDUSTRY briefSummary: Primary Objective: To further evaluate the aspects of safety related to PoNS therapy in chronic stroke survivors.
Exploratory Objectives: To further evaluate quality of life to measure physical, mental, behavioral, and general health, as well as functional decline (\> 30% on gait or balance improvement at endpoint) during the 12-week follow-up. conditions: Chronic Stroke Survivors studyType: INTERVENTIONAL phases: PHASE2 phases: PHASE3 allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 30 type: ESTIMATED name: Portable Neuromodulation Stimulator (PoNS) measure: Primary safety endpoints sex: ALL minimumAge: 18 Years maximumAge: 85 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Brooks Rehabilitation status: RECRUITING city: Jacksonville state: Florida zip: 32216 country: United States name: Mark Bowden, PhD. PT role: CONTACT phone: 904-345-6626 email: Mark.Bowden@Brooksrehab.org lat: 30.33218 lon: -81.65565 facility: Shepherd Center status: RECRUITING city: Atlanta state: Georgia zip: 30309 country: United States name: Cathy Furbish, PT, DPT, CCRP role: CONTACT phone: 404-350-7591 email: cathy.furbish@shepherd.org lat: 33.749 lon: -84.38798 facility: Neurology Center of New England, P.C. status: RECRUITING city: Foxboro state: Massachusetts zip: 02035 country: United States name: Rachel O'Donnell role: CONTACT phone: 781-551-5812 phoneExt: 101 email: rodonnell@myneurodr.com name: MD role: CONTACT lat: 42.06538 lon: -71.24783 facility: Rehabologym Corp status: RECRUITING city: Tarrytown state: New York zip: 10591 country: United States name: Avrielle Peltz, MA OTR/L role: CONTACT phone: 914-603-8600 email: avrielle.peltz@rehabologym.com lat: 41.07621 lon: -73.85875 hasResults: False
nctId: NCT06336707 id: HS-20089-103 briefTitle: HS-20089 Combination Treatment in Subjects With Advanced Solid Tumors overallStatus: NOT_YET_RECRUITING date: 2024-04-08 date: 2026-04-08 date: 2028-04-08 date: 2024-03-29 date: 2024-03-29 name: Hansoh BioMedical R&D Company class: INDUSTRY briefSummary: HS-20089 is an investigational antibody-drug conjugate (ADC) composed of a humanized IgG1 anti-B7-H4 monoclonal antibody conjugated to the topoisomerase I inhibitor payload via a protease-cleavable linker, with an average drug-to-antibody ratio of about 6.
This is a phase Ⅰ, open-label, multi-center study to evaluate the safety, tolerability, pharmacokinetics (PK) and efficacy of HS-20089 in combination with other antitumor agents (Adebrelimab with or without platinum; Bevacizumab with or without platinum) in subjects with advanced solid tumors. conditions: Advanced Solid Tumors studyType: INTERVENTIONAL phases: PHASE1 allocation: NON_RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: NONE count: 1048 type: ESTIMATED name: HS-20089 name: Adebrelimab name: Bevacizumab name: Cisplatin / carboplatin measure: Maximum tolerated dose (MTD) or maximum applicable dose (MAD) of HS-20089 in combination therapy measure: Incidence and severity of adverse events (AEs) measure: Observed maximum plasma concentration (Cmax) of HS-20089 measure: Time to reach maximum plasma concentration (Tmax) of HS-20089 following the first dose measure: Area under plasma concentration versus time curve from zero to last sampling time (AUC0-t) following the first dose of HS-20089 measure: Area under the plasma concentration versus time curve from time zero to infinity (AUC0-∞) after single dose of HS-20089 measure: Objective response rate (ORR) assessed by investigators according to Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 measure: Duration of response (DoR) assessed by investigators according to RECIST 1.1 measure: Disease control rate (DCR) assessed by investigators according to RECIST 1.1 measure: Progression-free survival (PFS) assessed by investigators according to RECIST 1.1 measure: Overall survival (OS) measure: Percentage of participants with antibodies to HS-20089 in serum sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False